We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+89.28%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
+$188M
Cap. Flow
+$206M
Cap. Flow %
41.36%
Top 10 Hldgs %
50.9%
Holding
101
New
48
Increased
19
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$44.5M
2
DNLI icon
Denali Therapeutics
DNLI
+$14.8M
3
BHVN icon
Biohaven
BHVN
+$12.3M
4
WVE icon
Wave Life Sciences
WVE
+$9.79M
5
ARGX icon
argenx
ARGX
+$8.22M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.6M
2
MRUS
Merus
MRUS
+$14M
3
ACLX
Arcellx
ACLX
+$13.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATAI icon
76
AtaiBeckley Inc
ATAI
$2.66B
$402K 0.08%
+76,032
New +$309K
CLPT icon
77
ClearPoint Neuro
CLPT
$454M
$363K 0.07%
+16,651
New +$196K
IVVD icon
78
Invivyd
IVVD
$219M
$306K 0.06%
+278,608
New +$247K
IVA
79
Inventiva
IVA
$1.09B
$178K 0.04%
+30,824
New +$134K
IONS icon
80
CALL
Ionis Pharmaceuticals
IONS
$8.99B
$138K 0.03%
+50,000
New +$2.44M
CRSP icon
81
CALL
CRISPR Therapeutics
CRSP
$4.71B
$59K 0.01%
+40,000
New +$2.3M
SNDX icon
82
CALL
Syndax Pharmaceuticals
SNDX
$2.02B
$55K 0.01%
+100,000
New +$1.31M
IMVT icon
83
CALL
Immunovant
IMVT
$8.27B
$50K 0.01%
250,000
+150,000
+150% +$2.43M
ARKG icon
84
CALL
ARK Genomic Revolution ETF
ARKG
$1.61B
$30K 0.01%
+200,000
New +$5.05M
SRRK icon
85
CALL
Scholar Rock
SRRK
$6.33B
$23.9K ﹤0.01%
+18,400
New +$644K
AKRO
86
PUT
DELISTED
Akero Therapeutics
AKRO
$9.69K ﹤0.01%
+15,500
New +$751K
ABUS icon
87
CALL
Arbutus Biopharma
ABUS
$901M
$9.5K ﹤0.01%
+95,000
New +$349K
APGE icon
88
Apogee Therapeutics
APGE
$10.1B
– –
-84,466
Closed -$3.67M
EYPT icon
89
EyePoint Inc
EYPT
$1.12B
– –
-329,254
Closed -$3.1M
GERN icon
90
CALL
Geron
GERN
$924M
– –
-300,000
Closed -$52.5K
GERN icon
91
Geron
GERN
$924M
– –
-6,649,244
Closed -$9.38M
JANX icon
92
Janux Therapeutics
JANX
$992M
– –
-89,933
Closed -$2.08M
LEGN icon
93
Legend Biotech
LEGN
$4.31B
– –
-270,144
Closed -$9.59M
MRUS
94
DELISTED
Merus
MRUS
– –
-266,094
Closed -$14M
NUVL
95
DELISTED
Nuvalent
NUVL
– –
-59,828
Closed -$4.56M
PRAX icon
96
Praxis Precision Medicines
PRAX
$8.77B
– –
-32,255
Closed -$1.36M
REGN icon
97
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-4,672
Closed -$2.45M
ROIV icon
98
CALL
Roivant Sciences
ROIV
$24.8B
– –
-915,000
Closed -$618K
VRNA
99
DELISTED
Verona Pharma
VRNA
– –
-7,407
Closed -$701K
ZLAB icon
100
Zai Lab
ZLAB
$2.28B
– –
-250,438
Closed -$8.76M
1 2 3
4
5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Stempoint Capital held 101 positions worth $499M, up 60% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $206M of net new capital in Q3 2025, opening 48 new positions and adding to 19 existing holdings. Its largest new stake was argenx: 12,465 shares worth $9.19M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $16.6M trimmed.

  • Stempoint Capital's largest Q3 2025 buy was argenx: 12,465 shares worth $9.19M.
  • Stempoint Capital added most to Roivant Sciences in Q3 2025, an estimated $44.5M increase.
  • Stempoint Capital's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $16.6M.
  • Stempoint Capital fully exited Merus in Q3 2025, selling an estimated $14M.
  • Stempoint Capital's ten largest holdings make up 51% of its $499M portfolio in Q3 2025.
  • Stempoint Capital opened 48 new positions and closed 14 in Q3 2025.
  • Stempoint Capital's portfolio value rose 60% quarter-over-quarter to $499M.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.